consider
success
made
mani
peptid
antigen
formul
peptidebas
vaccin
emerg
next
gener
prophylact
remedi
immunotherapi
howev
find
optim
platform
balanc
requir
effect
specif
safe
immun
respons
remain
major
challeng
mani
infecti
chronic
diseas
review
outlin
peptid
immunogen
influenc
way
peptid
present
immun
system
underscor
need
multifunct
deliveri
system
coupl
antigen
adjuv
singl
construct
particular
attent
given
abil
tolllik
receptor
agonist
act
adjuv
survey
recent
approach
develop
peptid
antigen
deliveri
system
given
mani
incorpor
tolllik
receptor
agonist
design
adjuv
antigen
deliveri
system
liposom
micel
nanoparticl
peptid
subunit
vaccin
tolllik
receptor
viruslik
particl
common
vaccin
formul
contain
inactiv
pathogen
kill
pathogen
pathogensecret
toxin
great
success
use
vaccin
correspond
type
infecti
diseas
mani
pathogen
amen
tradit
approach
problem
includ
inflamm
unwant
host
reaction
revers
virul
inabl
effect
cultur
bacteria
viru
possibl
induc
autoimmun
respons
need
refriger
storag
reason
shift
toward
develop
subunit
vaccin
contain
short
specif
fragment
pathogen
noninfecti
lack
potenti
replic
host
ration
approach
vaccin
design
aim
creat
vaccin
safer
immunolog
defin
compar
tradit
empir
approach
synthet
peptid
attract
consider
attent
basi
subunit
vaccin
design
peptid
play
critic
role
determin
magnitud
specif
cellmedi
cell
humor
antibodi
immun
contain
minim
sequenc
necessari
immunomodul
deliv
correctli
peptid
harbor
bor
tcell
receptor
epitop
suffici
elicit
effect
immun
respons
addit
stimul
protect
respons
particular
pathogen
peptidebas
immunotherapi
also
use
treat
chronic
ailment
cancer
develop
immun
suppress
autoimmun
diseas
furthermor
peptid
easili
synthes
character
gener
stabl
whole
pathogen
fulllength
protein
although
promis
candid
next
gener
immunotherapeut
peptid
typic
poorli
immunogen
use
alon
vaccin
reli
deliveri
potent
immunostimulatori
adjuv
effect
activ
innat
adapt
arm
immun
system
mani
type
vaccin
adjuv
becom
avail
sinc
date
approv
human
use
consequ
slow
develop
synthet
peptid
vaccin
signific
advanc
engin
adjuv
past
decad
tolllik
receptor
tlr
agonist
novel
particul
deliveri
system
made
peptidebas
vaccin
viabl
option
modern
immunotherapi
evidenc
recent
surg
public
preclin
studi
well
numer
human
trial
current
underway
review
examin
broad
rang
peptid
antigen
deliveri
system
present
current
literatur
focu
use
tlr
agonist
adjuv
understand
role
peptid
play
immun
differ
peptid
properti
affect
immun
system
recogn
respond
import
develop
strategi
peptidebas
immunotherapi
ultim
way
peptid
present
immun
system
determin
peptid
recogn
process
consequ
whether
appropri
immun
respons
follow
specif
properti
differ
peptid
antigen
profound
effect
immun
recognit
ensu
respons
exampl
evid
suggest
order
highli
repetit
display
antigen
seen
bacteri
polysaccharid
viral
glycoprotein
may
import
trigger
humor
respons
specif
multival
present
antigen
induc
prolifer
antibodyproduc
b
cell
independ
tcell
help
crosslink
adjac
membranebound
immunoglobulin
molecul
bcell
surfac
ie
antigenspecif
bcell
receptor
activ
b
cell
rapidli
secret
pentamer
antibodi
compens
low
antigen
affin
fight
initi
infect
allow
time
antibodi
affin
matur
tcell
recruit
memori
cell
develop
also
report
howev
second
signal
need
stimul
secret
antibodi
activ
b
cell
presum
confirm
antigen
foreign
selfderiv
understand
physic
paramet
influenc
bcell
receptor
crosslink
activ
valuabl
ration
engin
peptid
vaccin
particularli
design
elicit
strong
humor
respons
exampl
averag
distanc
bind
site
adjac
receptor
calcul
nm
distanc
repetit
epitop
number
antigen
capabl
crosslink
bcell
receptor
shown
averag
nm
estim
receptor
need
crosslink
per
cluster
small
number
cluster
necessari
bcell
prolifer
investig
level
order
rigid
multival
antigen
would
benefici
subunit
vaccin
design
nevertheless
antigen
deliveri
system
present
multipl
copi
antigen
peptid
singl
complex
thu
increas
local
antigen
concentr
provid
multival
potenti
gener
signific
antigenspecif
immun
respons
deliveri
system
capabl
multival
peptid
display
inde
develop
includ
dendrimer
multipl
antigen
peptid
system
first
introduc
tam
colleagu
built
upon
other
well
number
creativ
recent
design
discuss
later
review
conform
integr
anoth
caus
weak
immunogen
peptid
taken
nativ
environ
within
protein
typic
contain
enough
structur
inform
fold
correctli
regard
stimul
antibodi
respons
import
bcell
recogn
specif
sequenc
specif
shape
target
peptid
epitop
share
similar
structur
assum
sequenc
target
protein
result
antibodi
probabl
crossreact
protein
consequ
unless
desir
epitop
fall
within
unstructur
region
protein
eg
loop
turn
peptidebas
vaccin
must
promot
peptid
secondari
structur
order
induc
antigenspecif
humor
respons
mani
sequencebas
algorithm
develop
predict
bcell
epitop
howev
even
combin
particularli
accur
recent
method
take
account
protein
structur
success
still
far
abl
reliabl
predict
exact
bcell
epitop
approach
mimick
nativ
peptid
structur
prove
success
illustr
trial
use
conformationdepend
epitop
found
coiledcoil
protein
group
streptococcu
ga
bacterium
synthet
peptid
repres
protect
bcell
epitop
within
ga
protein
conserv
region
possess
correct
helic
structur
bcell
epitop
integr
howev
flank
peptid
sequenc
possess
propens
fold
result
antibodi
opson
protect
mice
ga
infect
enhanc
peptid
secondari
structur
also
demonstr
protein
analog
micel
micel
selfassembl
peptid
amphiphil
consist
hydrophil
peptid
conjug
hydrophob
alkyl
tail
upon
selfassembl
shown
short
collagen
peptid
regain
triplehel
structur
dnabind
peptid
regain
structur
approach
enhanc
antigen
structur
involv
use
peptid
scaffold
known
templateassoci
synthet
protein
sequenti
oligopeptid
carrier
rather
recogn
nativ
intact
antigen
b
cell
cell
specif
recogn
process
antigen
fragment
bound
mhc
molecul
locat
surfac
antigenpres
cell
apc
reason
peptid
conform
critic
factor
stimul
cell
properti
peptid
length
peptidemhc
interact
studi
aid
identif
tcell
epitop
mhc
class
molecul
display
peptid
cytotox
cell
c
cell
mhc
class
ii
molecul
display
peptid
helper
cell
th
cell
possess
antigenbind
cleft
compos
antiparallel
floor
bound
two
cleft
line
pocket
highli
polymorph
amino
acid
serv
basi
antigen
restrict
mhci
molecul
conserv
residu
resid
end
bind
cleft
involv
hydrogenbond
interact
termini
bound
peptid
antigen
effect
limit
length
antigen
approxim
amino
acid
mhcii
molecul
lack
hydrogenbond
residu
consequ
allow
antigen
protrud
end
cleft
peptid
bound
mhcii
molecul
tend
approxim
amino
acid
length
consider
longer
interestingli
shown
minim
c
cell
peptid
epitop
load
onto
mhci
molecul
present
surfac
apc
without
undergo
natur
intracellular
process
simpli
use
minim
length
tcell
peptid
epitop
howev
necessarili
best
strategi
longer
peptid
must
taken
apc
undergo
process
cleav
load
onto
appropri
mhc
molecul
transport
cell
surfac
ensur
proper
present
peptid
epitop
incorpor
longer
peptid
contain
repeat
multipl
epitop
flank
nonepitop
sequenc
shown
effect
stimul
immun
respons
sever
predict
algorithm
avail
attempt
predict
peptid
sequenc
fit
mhc
molecul
type
bioinformat
tool
gener
success
use
predict
bcell
epitop
still
total
accur
vitro
test
aim
rapidli
easili
identifi
appropri
epitop
includ
highthroughput
phage
display
microarray
also
develop
method
use
combin
greater
accuraci
result
peptid
still
need
verifi
vivo
ensur
abl
creat
immun
respons
robust
immun
respons
often
requir
stimul
th
cell
activ
th
cell
recruit
naiv
th
cell
c
cell
b
cell
provid
signal
necessari
amplifi
immun
respons
target
antigen
th
cell
also
initi
develop
memori
b
cell
provid
longlast
immun
antigen
upon
subsequ
exposur
small
synthet
peptid
design
induc
humor
cellmedi
immun
respons
usual
contain
appropri
thcell
epitop
therefor
alway
effect
vaccin
ad
constraint
thcell
stimul
high
degre
mhc
polymorph
incorpor
promiscu
thcell
epitop
bind
multipl
mhcii
allel
peptid
antigen
deliveri
system
repres
feasibl
solut
problem
tradit
method
strengthen
immunogen
peptid
antigen
coval
attach
larg
carrier
protein
keyhol
limpet
hemocyanin
diphtheria
toxoid
provid
sourc
thcell
epitop
use
carrier
approach
lead
product
immun
respons
peptid
antigen
number
drawback
carrier
protein
elicit
immun
respons
compet
even
suppress
respons
toward
peptid
antigen
antibodi
irrelev
specif
may
also
induc
construct
attach
peptid
incorrect
order
orient
limit
includ
amount
peptid
load
onto
carrier
dose
carrier
protein
safe
administ
rel
low
qualiti
control
achiev
circumv
problem
target
peptid
antigen
conjug
combin
short
peptid
sequenc
contain
defin
thcell
epitop
shown
vitro
anim
studi
provid
heighten
immun
respons
toward
target
peptid
littl
evid
immun
suppress
exampl
synthet
peptid
vaccin
base
lutein
hormonereleas
hormon
lhrh
play
central
role
reproduct
process
promiscu
thcell
epitop
formul
oilbas
emuls
adsorb
onto
aluminum
hydroxid
gel
vaccin
immunogen
rodent
dog
nonhuman
primat
baboon
antibodi
respons
specif
lhrh
peptid
contrast
conjug
lhrh
peptid
carrier
protein
small
portion
immun
respons
direct
peptid
note
howev
peptid
link
also
potenti
antibodi
gener
epitop
form
junction
tcell
bcell
epitopecontain
peptid
even
optim
bor
c
cell
epitop
appropri
thcell
epitop
peptidebas
immunotherapeut
still
requir
adjuv
effect
adjuv
broadli
defin
anyth
increas
immunestimulatori
behavior
antigen
adjuv
function
number
way
includ
provid
antigen
depot
increas
uptak
apc
shield
peptid
rapid
degrad
increas
peptid
halflif
andor
directli
activ
patternrecognit
receptor
prr
apc
mechan
involv
stimul
apc
directli
indirectli
especi
dendrit
cell
dc
dendrit
cell
provid
crucial
link
innat
adapt
immun
system
nonspecif
intern
process
antigen
present
result
antigen
peptid
sequencespecif
cell
prr
dc
stimul
immatur
dc
particip
innat
immun
respons
releas
variou
solubl
mediat
inflammatori
cytokin
type
interferon
ifn
immatur
dc
resid
peripher
tissu
lymphoid
tissu
dc
resid
peripher
tissu
migrat
region
lymph
node
upon
activ
activ
dc
initi
adapt
antigenspecif
immun
respons
process
antigen
present
naiv
cell
lymph
node
time
dc
upregul
mhc
class
ii
costimulatori
molecul
promot
interact
dc
cell
stimul
dc
shape
adapt
immun
control
type
qualiti
magnitud
immun
respons
memori
balanc
inflammatori
antiinflammatori
cytokin
product
dc
respect
crucial
determin
type
thcell
respons
exampl
drive
polar
th
cell
toward
respons
favor
stimul
c
cell
mediat
immun
pathogen
notabl
intracellular
pathogen
hand
regulatori
role
mediat
respons
lead
humor
immun
antiinflammatori
pathway
aluminum
hydroxid
phosphat
salt
commonli
call
alum
domin
adjuv
use
sinc
discoveri
alum
use
diphtheria
tetanu
hepat
b
vaccin
mechan
action
alum
debat
recent
research
suggest
alum
function
activ
dc
prr
known
inflammasom
addit
provid
depot
antigen
alum
often
effect
gener
humor
immun
ineffect
induc
cellmedi
immun
furthermor
aluminumbas
adjuv
case
associ
seriou
local
reaction
erythema
subcutan
nodul
contact
hypersensit
order
avoid
limit
alum
grow
need
new
adjuv
formul
mani
adjuv
emuls
function
manner
similar
alum
provid
peptid
antigen
depot
antigen
depot
enhanc
peptid
immunogen
concentr
peptid
extend
time
antigen
resid
bodi
thu
increas
probabl
interact
immun
cell
mani
antigen
depot
also
theoriz
creat
inflamm
stimul
recruit
apc
oilinwat
emuls
approv
adjuv
europ
theoriz
primarili
function
manner
creat
antigen
depot
peptid
vaccin
design
remain
use
strategi
illustr
phase
ii
clinic
trial
show
success
treatment
stage
vulvar
neoplasia
use
multipl
human
papillomaviru
hpv
peptid
emulsifi
incomplet
freund
adjuv
incomplet
freund
adjuv
waterinoil
emuls
phase
iii
clinic
trial
antigen
depot
effect
mani
situat
howev
knowledg
immun
system
grown
much
recent
vaccin
adjuv
research
aim
specif
activ
dc
target
prr
prr
germlin
encod
recogn
distinct
evolutionarili
conserv
microbi
structur
call
pathogenassoci
molecular
pattern
pamp
tlr
cytosol
receptor
nucleotidebind
oligomer
domainlik
receptor
famili
retinoicacidinduc
gene
ilik
receptor
inflammasom
lectin
receptor
mannos
receptor
type
prr
prr
may
suitabl
target
vaccin
adjuv
tlr
particularli
well
character
tlr
activ
dc
produc
primarili
immun
respons
although
respons
elicit
instanc
use
tlr
agonist
adjuv
shown
produc
higher
avid
tcell
clone
alum
differ
tlr
agonist
conjunct
model
antigen
immun
nonhuman
primat
also
shown
influenc
magnitud
qualiti
memori
tcell
respons
tlr
agonist
use
novel
adjuv
formul
combin
tradit
adjuv
alum
emuls
improv
efficaci
safeti
tlr
agonist
also
establish
clinic
trial
agonist
monophosphoryl
lipid
mpla
approv
human
use
europ
late
usa
coformul
alum
call
human
ten
function
tlr
tlr
tlr
highli
conserv
differ
organ
vari
number
tlr
vertebr
contain
least
one
tlr
six
major
tlr
famili
human
notabl
function
member
five
tlr
famili
contain
pseudogen
mice
major
experi
determin
tlr
function
carri
tlr
human
except
contain
three
addit
function
tlr
tlr
tolllik
receptor
function
either
homodim
heterodim
tlr
tlr
requir
help
protein
notabl
tlr
express
cell
surfac
migrat
phagosom
activ
tlr
recogn
nucleic
acid
motif
confin
endosom
compart
tlr
recogn
common
conserv
motif
ie
pamp
bacteria
virus
fungi
pathogen
tabl
ligand
tlr
identifi
form
dimer
recogn
variou
lipopeptid
recogn
bacteri
associ
lipopolysaccharid
lp
recogn
cpg
dna
unmethyl
cpgcontain
oligodinucleotid
odn
addit
natur
ligand
synthet
ligand
develop
mani
tlr
sever
synthet
imidazoquinolinelik
molecul
develop
mpla
develop
agonist
significantli
less
toxic
lp
tolllik
receptor
express
wide
varieti
cell
includ
b
cell
specif
type
cell
monocyt
dc
macrophag
certain
epitheli
cell
mani
innat
immun
cell
express
pattern
differ
cell
vari
differ
type
dc
also
differ
express
pattern
plasmacytoid
dc
critic
respond
viral
nucleic
acid
express
myeloid
dc
express
tlr
human
monocyt
express
tlr
earli
vaccin
adjuv
approv
without
exact
mechan
action
known
understand
way
new
adjuv
function
necessari
approv
aid
design
upon
bind
respect
ligand
tlr
initi
complex
intracellular
signal
pathway
result
creation
inflammatori
environ
adapt
immun
respons
figur
tlr
signal
review
detail
briefli
discuss
tlr
type
transmembran
protein
compos
extracellular
domain
contain
leucinerich
repeat
involv
recognit
pamp
cytoplasm
receptor
tir
domain
recruit
variou
tircontain
adapt
molecul
initi
intracellular
signal
cascad
two
independ
pathway
distinguish
tlr
signal
myeloid
differenti
primaryrespons
gene
depend
pathway
activ
upon
engag
tlr
except
bind
tlr
directli
tir
domain
adapterlik
tir
domaincontain
adapt
protein
shown
adapterlik
tir
domaincontain
adapt
protein
requir
low
ligand
concentr
recruit
lead
activ
receptorassoci
kinas
signal
molecul
eventu
activ
sever
mapk
key
transcript
factor
includ
activ
protein
ifn
regulatori
factor
lead
secret
cytokin
dc
matur
tirdomaincontain
adapt
induc
trif
depend
pathway
stimul
involv
ifn
regulatori
factor
product
activ
signal
transduc
activ
transcript
stimul
type
ifninduc
gene
trifrel
adapt
molecul
import
signal
mediat
stimul
tlr
signal
via
trifdepend
pathway
also
lead
activ
mapk
signal
pathway
pathogen
present
multipl
tlr
agonist
immun
system
shown
tlr
cooper
resist
infecti
diseas
sever
group
shown
stimul
multipl
tlr
result
synergist
upregul
cytokin
word
effect
two
tlr
agonist
immun
system
much
greater
singl
agonist
comprehens
evalu
differ
tlr
agonist
dc
shown
exhibit
synergist
upregul
inflammatori
cytokin
stimul
sever
tlr
agonist
combin
notabl
combin
suggest
tlr
agonist
signal
trifdepend
pathway
cooper
tlr
synergi
warger
et
al
show
synergi
trif
pathway
peptideload
dc
led
mark
increas
c
cell
effector
function
wildtyp
mice
vivo
tlr
agonist
also
shown
act
synergist
prr
much
room
explor
combin
agonist
work
best
case
howev
stimul
multipl
prr
specif
tlr
power
tool
induc
strong
immun
respons
could
benefici
mani
vaccin
formul
activ
tlr
without
risk
toxic
safeti
concern
given
strong
inflammatori
respons
stimul
tlr
agonist
tlr
involv
autoimmun
chronic
inflammatori
infecti
diseas
sepsi
perhap
seriou
caus
lp
overstimul
result
organ
failur
tlr
also
implic
diabet
atherosclerosi
neg
regulatori
pathway
exist
difficult
control
vaccin
set
agonist
shown
abl
break
toler
caus
autoimmun
diseas
anim
model
repeat
exposur
singl
tlr
agonist
shown
induc
tand
natur
killer
cell
immunosuppress
fact
certain
virus
shown
util
immunosuppress
avoid
immun
recognit
also
shown
stimul
tlr
necessari
gener
antibodi
respons
suggest
vaccin
strategi
avoid
may
still
abl
stimul
immun
system
would
avoid
risk
associ
tlr
stimul
howev
demonstr
tlr
agonist
significantli
enhanc
vaccin
efficaci
lead
appropri
cellular
antibodi
respons
concern
use
tlr
agonist
highlight
need
effect
deliveri
vehicl
minim
risk
associ
maxim
benefit
deliv
antigen
peptid
tlr
agonist
promis
direct
develop
new
immunotherapeut
howev
determin
type
adjuv
peptid
epitop
includ
design
part
stori
outlin
immunogen
depend
peptid
antigen
adjuv
recogn
immun
system
rout
administr
specif
vaccin
formul
profound
effect
factor
peptid
orient
structur
stabil
peptid
degrad
clearanc
tissu
local
antigen
uptak
process
toxic
factor
consid
optim
peptidebas
vaccin
present
multifunct
deliveri
system
address
issu
promot
safe
robust
immun
respons
promis
approach
taken
deliv
peptid
antigen
adjuv
togeth
includ
coval
link
peptid
tlr
agonist
deliv
peptid
adjuv
togeth
novel
particul
carrier
figur
effect
immun
respons
peptid
antigen
apc
process
antigen
time
stimul
adjuv
fact
shown
antigen
tlr
agonist
coloc
phagosom
effici
mhcii
antigen
present
coval
link
tlr
agonist
peptid
antigen
perhap
straightforward
way
ensur
apc
encount
antigen
adjuv
lipopeptid
proven
effect
synthet
selfadjuv
vaccin
also
function
least
part
stimul
importantli
enhanc
peptid
immunogen
seen
peptid
lipid
coupl
simpli
mix
togeth
furthermor
demonstr
linker
locat
linker
chemistri
number
lipid
group
significantli
influenc
immun
respons
note
ad
advantag
amphiphil
construct
act
modular
build
block
selfassembl
structur
liposom
micel
mani
peptid
antigenlipid
conjug
explor
simpl
design
attach
singl
palmit
acid
moieti
antigen
peptid
shown
enhanc
peptid
immunogen
manner
jackson
cowork
report
conjug
antigen
peptid
dipalmitoylsglyceryl
cystein
pam
cy
gener
antigenspecif
immun
respons
wide
varieti
anim
studi
studi
includ
evalu
bcell
epitop
contracept
therapi
c
cell
epitop
hepat
c
viru
influenza
viru
intracellular
bacterium
listeria
monocytogen
model
tumor
antigen
ovalbumin
anoth
sophist
design
oliv
cowork
shown
lipidcor
peptid
link
synthet
analog
pam
cy
ie
lipoamino
acid
multipl
peptid
via
dendrimer
multipl
antigen
peptid
structur
effect
ga
vaccin
system
allow
deliveri
multipl
peptid
one
complex
make
possibl
includ
differ
epitop
may
need
achiev
broadspectrum
immun
addit
stimul
lipidcor
peptid
lipopeptid
report
cross
mucos
surfac
allow
needlefre
vaccin
capabl
induc
igamedi
mucos
immun
clinic
trial
demonstr
safeti
efficaci
lipopeptid
vaccin
includ
hiv
hpv
antigen
also
coupl
tlr
agonist
shown
coval
link
gag
protein
synthet
ligand
imidazoquinolinelik
molecul
effect
gener
gagspecif
c
cell
simpli
codeliv
induc
strong
respons
anoth
exampl
cpgantigen
conjug
shown
effect
codeliveri
even
compet
live
viru
vaccin
due
enhanc
antigen
crosspresent
stimul
dc
support
result
khan
colleagu
demonstr
link
either
pam
cy
cpg
peptid
antigen
increas
antigen
uptak
crosspresent
dc
although
uptak
mechan
differ
coval
link
tlr
agonist
peptid
option
coupl
two
exampl
complex
posit
charg
peptid
neg
charg
poli
c
synthet
dsrna
agonist
capabl
effect
stimul
tumor
regress
human
cervic
cancer
model
tumor
preestablish
mice
particul
deliveri
system
shown
promis
wide
varieti
field
incorpor
multipl
function
one
particl
exampl
modular
micel
selfassembl
peptid
amphiphil
develop
target
tumor
deliv
therapeut
peptid
atherosclerot
plaqu
vivo
mice
similarli
modular
multifunct
vaccin
platform
incorpor
peptid
epitop
adjuv
target
appropri
immun
cell
specif
compon
multifunct
carrier
vari
wide
common
theme
form
type
nanoor
microscal
particul
shown
carrier
often
exhibit
selfadjuv
behavior
bacteria
virus
also
roughli
defin
particul
similar
size
suggest
particul
design
gener
could
act
anoth
type
pamp
impart
enhanc
immunogen
precis
size
vaccin
particl
influenc
biodistribut
mechan
particl
uptak
thu
influenc
type
level
result
immun
respons
larg
particl
primarili
taken
macrophag
via
phagocytosi
wherea
microparticl
rang
size
predominantli
taken
macropinocytosi
viruss
particl
diamet
approxim
nm
taken
dc
endocytosi
via
clathrinco
pit
caveola
specif
receptor
understand
size
may
critic
factor
vaccin
design
plebanski
colleagu
examin
uptak
immunogen
peptid
antigenco
bead
rang
nm
diamet
found
nm
particl
preferenti
taken
dc
promot
significantli
stronger
cellmedi
respons
larger
particl
larger
particl
mainli
taken
macrophag
capabl
induc
consider
antibodi
respons
later
studi
show
peptideco
bead
within
narrow
size
rang
nm
could
differenti
affect
cytokin
product
moreov
shown
particl
less
nm
diamet
effici
taken
lymphat
vessel
interstiti
flow
transport
region
drain
lymph
node
concentr
popul
dc
particl
greater
nm
gener
remain
near
site
administr
obviou
one
specif
size
rang
optim
vaccin
formul
clear
control
size
vaccin
particl
could
mean
bia
immun
respons
asid
size
multitud
function
engin
particulatebas
vaccin
particl
display
multival
array
peptid
potenti
crosslink
bcell
receptor
initi
strong
antibodi
respons
particulatebas
vaccin
also
encapsul
peptid
protect
degrad
act
depot
antigen
releas
time
cellspecif
ligand
integr
particl
activ
target
addit
adjuv
incorpor
amplifi
direct
immun
respons
larg
number
particul
deliveri
system
encompass
wide
rang
size
nm
materi
natur
synthet
develop
peptidebas
immunotherapi
mani
case
immunostimulatori
properti
particl
significantli
enhanc
addit
tlr
agonist
lipidbas
carriersliposom
versatil
platform
construct
multifunct
peptid
antigen
carrier
liposom
consist
lipid
bilay
compos
natur
synthet
phospholipid
surround
aqueou
core
liposom
made
larg
multilamellar
structur
sever
micron
diamet
correct
lipid
composit
made
rang
size
approxim
nm
use
techniqu
sonic
extrus
peptid
antigen
conjug
lipid
display
liposom
membran
encapsul
liposom
core
lipid
use
anchor
peptid
liposom
agonist
addit
tlr
agonist
mpla
also
incorpor
liposom
bilay
clinic
trial
lipopeptid
mpla
liposom
bilay
conduct
prove
safe
effect
nonsmallcel
lung
cancer
incorpor
tlr
neg
charg
odn
agonist
complex
posit
charg
lipid
liposom
deliveri
small
molecul
synthet
agonist
encapsul
liposom
core
report
combin
tlr
agonist
peptid
antigen
function
optim
peptid
antigen
tlr
agonist
present
liposom
addit
simultan
deliv
tlr
agonist
peptid
antigen
liposom
also
serv
protect
tlr
agonist
degrad
particularli
import
regard
odn
vulner
abund
nucleas
bodi
liposom
also
use
target
peptid
antigen
dc
may
target
dc
passiv
preferenti
taken
dc
base
particul
natur
attach
activ
target
ligand
mannosyl
lipid
antibodi
also
shown
increas
efficaci
liposom
antigen
carrier
liposom
also
capabl
target
content
endosom
tlr
antigen
mhc
pathway
composit
liposom
import
variabl
shown
increas
membran
fluiditi
enhanc
antibodi
respons
taneichi
et
al
show
antigen
coupl
liposom
use
satur
unsatur
fatti
acid
induc
respons
ovalbumin
peptid
shown
satur
fatti
acid
antigen
process
peptid
display
mhc
class
molecul
peptid
deriv
antigen
link
unsatur
fatti
acid
display
mhc
class
ii
pathway
mani
liposom
consid
less
inert
carrier
protect
antigen
degrad
deliv
antigen
apc
lipid
function
adjuv
absenc
immunostimulatori
molecul
includ
liposom
form
differ
bacteri
lipid
extract
may
actual
stimul
tlr
variou
combin
cation
lipid
howev
mani
liposom
shown
need
addit
adjuv
order
effect
anoth
lipidbas
antigen
deliveri
strategi
form
immunostimulatori
complex
peptid
antigen
embed
hollow
diamet
particl
compris
phospholipid
cholesterol
plantderiv
immunostimulatori
saponin
quil
csl
behr
pa
usa
vaccin
made
mix
peptid
antigen
preform
particl
shown
induc
strong
antigenspecif
cellmedi
andor
humor
immun
respons
wide
rang
antigen
includ
bacteri
viral
parasit
cancer
antigen
iscomatrix
vaccin
approv
veterinari
use
current
undergo
clinic
trial
human
use
known
adjuv
properti
particl
due
least
part
stimul
pathway
seem
independ
activ
tlr
exosom
natur
occur
vesicl
diamet
nm
thought
involv
celltocel
commun
includ
immun
cell
select
remov
membran
protein
exploit
anoth
type
liposom
antigen
carrier
exosom
secret
mani
differ
type
cell
often
contain
mhc
class
ii
molecul
well
costimulatori
molecul
demonstr
deliv
peptid
dc
exosom
far
effect
deliv
free
peptid
one
first
studi
show
exosom
present
antigen
peptid
induc
protect
immun
respons
perform
alin
colleagu
toxoplasma
gondiipuls
dcderiv
exosom
stimul
antigenspecif
humor
cellmedi
respons
pathogen
howev
evid
exosom
requir
addit
adjuv
effect
prime
naiv
c
cell
respons
vivo
support
combin
exosom
dsrna
cpg
odn
agonist
shown
success
activ
c
cell
lead
tumor
reject
mice
number
formul
develop
cancer
immunotherapi
enter
clinic
trial
viruslik
particlesanoth
design
rout
deliv
peptid
antigen
incorpor
noninfecti
nonrepl
viruslik
particl
vlp
vlp
made
recombin
viral
envelop
andor
capsid
protein
selfassembl
diamet
structur
capabl
display
multipl
antigen
peptid
surfac
peptid
deriv
either
parent
viru
genet
insert
fusion
foreign
antigen
epitop
chemic
conjug
peptid
preassembl
vlp
one
influenza
vaccin
avail
use
adjuv
made
type
vlp
call
virosom
market
inflex
v
crucel
netherland
mani
vlp
formul
current
clinic
preclin
studi
vlpbase
hepat
b
viru
hpv
vaccin
licens
human
use
pathogen
proven
challeng
vlp
vaccin
directli
infect
immun
cell
develop
mechan
evad
immun
system
undergo
rapid
genet
drift
number
studi
show
addit
tlr
agonist
addit
adjuv
aid
effect
vlp
exampl
cpg
odn
packag
insid
vlp
display
lymphocyt
choriomening
viru
c
cell
epitop
stimul
product
antigenspecif
c
cell
cure
mice
virusinduc
tumor
singl
dose
vlp
vaccin
anoth
exampl
ligand
flagellin
anchor
h
n
influenza
vlp
compar
vlp
construct
without
flagellin
flagellin
vlp
induc
higher
level
specif
igg
antibodi
mice
vlp
provid
full
protect
viral
challeng
interestingli
howev
vlp
flagellin
result
superior
protect
standard
vlp
upon
challeng
heterosubtyp
viru
h
n
demonstr
potenti
crossprotect
vlp
vaccin
enhanc
immunogen
also
seen
anoth
influenza
virosom
vaccin
upon
incorpor
nontox
lp
analog
biodegrad
polym
solidcor
beadssynthet
particl
made
degrad
polym
polylactidecoglycolid
poli
llacticcoglycol
acid
plga
poli
llactid
poli
ortho
ester
wide
explor
peptid
antigen
deliveri
vehicl
serv
antigen
reservoir
slowli
releas
peptid
day
week
even
month
dictat
particl
degrad
rate
potenti
elimin
need
booster
diamet
biocompat
particl
rang
nm
depend
composit
method
prepar
shown
microparticl
undergo
rapid
phagocytosi
macrophag
dc
vitro
vivo
variou
polymer
microand
nanoparticl
demonstr
immunestimulatori
behavior
enhanc
coformul
peptid
tlr
agonist
exampl
singl
dose
plga
nanoparticl
load
hepat
b
viru
peptid
antigen
mpla
induc
significantli
stronger
cellmedi
respons
predomin
profil
mice
use
free
antigen
free
antigen
mpla
particl
load
antigen
altern
tlr
agonist
adsorb
onto
particl
surfac
recent
work
demonstr
exampl
abil
poli
c
coat
plga
particl
prime
dc
matur
anoth
design
enhanc
immunogen
seen
peptid
antigen
adsorb
anion
surfac
polylactidecoglycolid
microparticl
mean
size
contain
either
encapsul
mpla
synthet
lp
recent
new
type
biodegrad
particl
describ
viral
peptid
epitop
encapsul
sio
templat
hydrogel
capsul
shown
activ
c
cell
ex
vivo
materi
like
gold
silica
latex
polystyren
also
use
form
solidcor
nanobead
peptidebas
immunotherapi
peptideconjug
nanobead
without
addit
adjuv
stimul
humor
andor
cellmedi
respons
exampl
demonstr
sheep
multipl
peptid
footandmouth
viru
either
conjug
separ
individu
nmpolystyren
nanobead
conjug
mixtur
peptid
bead
possibl
adjuv
properti
peptideconjug
nanobead
simpli
due
viruslik
size
allow
interact
dc
correl
nanobead
size
immunogen
fifi
colleagu
show
polystyren
nanoparticl
conjug
tumor
antigen
administ
mice
coloc
dc
lymph
node
provid
prophylact
therapeut
effect
vaccin
develop
complex
daunt
endeavor
yet
time
enorm
potenti
peptidebas
immunotherapi
design
ration
engin
peptid
antigen
deliveri
system
gener
safer
effect
immunotherapi
tradit
pathogenbas
vaccin
deliveri
system
potenti
minim
side
effect
target
specif
apc
link
antigen
adjuv
allow
greater
qualiti
control
easier
valid
addit
peptidebas
vaccin
use
prophylaxi
also
therapeut
treatment
evid
progress
made
mani
peptidebas
formul
tlr
agonist
adjuv
enter
clinic
trial
alreadi
licens
use
main
challeng
face
field
bring
vaccin
market
peptidebas
vaccin
slow
reach
commerci
larg
due
safeti
concern
regard
accompani
adjuv
necessarili
lack
efficaci
comprehens
evalu
latest
design
next
step
realli
advanc
peptidebas
immunotherapi
next
level
similarli
systemat
experi
need
defin
combin
properti
form
safest
effect
vaccin
effici
evalu
vaccin
candid
appli
lesson
learn
new
vaccin
design
translat
result
laboratori
clinic
eventu
market
heighten
level
commun
scientist
clinician
stage
vaccin
develop
crucial
recurr
theme
recent
peptidebas
immunotherapi
studi
trigger
adapt
antigenspecif
respons
first
stimul
innat
immun
system
thu
next
gener
vaccin
larg
design
deliv
defin
antigen
peptid
target
dc
eg
size
receptor
bind
andor
potenti
peptid
immunogen
via
prr
agonist
combin
particul
carrier
tlr
agonist
prove
especi
product
new
vaccin
may
also
incorpor
multipl
tlr
prr
agonist
order
take
advantag
synergist
effect
cytokin
product
enhanc
immun
respons
success
tlrstimul
peptid
vaccin
next
year
correl
progress
understand
tlr
agonist
adjuvant
find
balanc
effect
immun
stimul
potenti
excess
inflammatori
respons
safeti
concern
result
peptidebas
vaccin
first
impact
diseas
benefit
use
vaccin
larg
cancer
hiv
make
potenti
risk
associ
adjuv
use
accept
alreadi
evid
major
ongo
vaccin
clinic
trial
vaccin
come
market
provid
new
tool
control
major
global
diseas
difficult
control
mean
grow
knowledg
immunolog
mechan
adjuv
action
includ
identifi
role
specif
signal
pathway
import
regul
adapt
immun
antigen
recognit
process
present
peptidebas
vaccin
becom
increasingli
tailor
therefor
effect
therapeut
challeng
sculpt
adapt
immun
achiev
desir
outcom
immunotherapi
prevent
treat
infecti
chronic
diseas
peptid
vaccin
efficaci
determin
peptid
recogn
process
immun
system
specif
peptid
concentr
multival
secondari
structur
length
presenc
helper
tcell
epitop
significantli
affect
elicit
immun
respons
solubl
peptid
alon
weakli
immunogen
usual
need
coadminist
potenti
toxic
adjuv
adjuv
larg
function
stimul
innat
immun
system
particularli
activ
dendrit
cell
dc
dc
critic
link
innat
adapt
arm
immun
system
conserv
microbi
motif
trigger
innat
respons
includ
bind
tolllik
receptor
tlr
surfac
dc
antigenpres
cell
apc
multipl
tlr
ligand
act
synergist
upregul
cytokin
product
dc
initi
differ
type
immun
respons
tlr
agonist
elicit
strong
inflammatori
respons
one
major
hurdl
use
vaccin
deliv
way
ensur
accept
safeti
profil
link
peptid
antigen
tlr
agonist
singl
construct
proven
effect
approach
enhanc
peptid
immunogen
mani
sophist
design
deliv
antigen
peptid
adjuv
explor
includ
direct
peptideadjuv
conjug
particul
system
liposom
viruslik
particl
degrad
polym
nondegrad
solidcor
bead
deliveri
vehicl
coupl
peptid
antigen
tlr
agonist
immunestimul
properti
dc
target
multival
peptid
display
addit
adjuv
activ
provid
protect
degrad
peptidebas
vaccin
incorpor
nanos
particul
carrier
demonstr
consider
potenti
new
improv
prophylact
remedi
immunotherapeut
